BNGO Bionano Genomics, Inc.
Bionano Genomics, Inc. (BNGO) is expected to report earnings on February 9, 2027, after the market close. The stock has had a Post-Earnings Announcement Drift (PEAD) of -18.6% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Bionano Genomics, Inc.
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business.
Sector
Healthcare
Industry
Medical Instruments/Supply
Charts powered in part by Lightweight Charts™ by TradingView.